Sponsor content

N6, A Novel, Broad, Highly Potent HIV-specific Antibody

Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies.​

N6 is a newly discovered antibody at NIAID. It has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies.N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutralizes 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently. Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies.

Potential Commercial Applications:

  • HIV therapeutic
  • HIV prophylactic

Competitive Advantages:

Neutralized 98 percent of HIV isolates tested

Neutralized 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently.

Development Stage:Pre-Clinical

Inventors:Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng, all of NIAID.

Publications:Huang, Jinghe, et al. "Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth." Immunity 45.5 (2016): 1108-1121.

Intellectual Property:HHS Reference No. E-131-2015 et seq. – US provisional application 62/136,228, US provisional application 62/250,378, and PCT application PCT/US2016/023145.

Licensing and Collaborative Research Opportunity:The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in licensing or collaborative research to further co-develop this technology. For opportunities, please contact Chris Kornak, 240-627-3705, chris.kornak@nih.gov


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.